`
`Journaliss
`
`Blog
`
`Log In
`
`Sign Up
`
`Send a Release
`
`News
`
`Solutions
`
`Resources
`
`Search
`
`News in Focus Business & Money Science & Tech
`
`Lifesyle & Health Policy & Public Interes People & Culture
`
`Physician General, Montgomery
`County Commissioner and Adapt
`Pharma Representative Fill Naloxone
`Prescription and Discuss the Fight
`agains Pennsylvania's Opioid
`Epidemic
`
`
`
`NEWS PROVIDED BY
`Pennsylvania Department of Health
`Jan 11, 2017, 14:30 ET
`
`
`
`SHARE THIS ARTICLE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONSHOHOCKEN, Pa., Jan. 11, 2017 /PRNewswire-USNewswire/ -- Pennsylvania
`Physician General Dr. Rachel Levine, Montgomery County Commissioner Dr.
`Valerie Arkoosh, and Matt Ruth of Adapt Pharma visited Weis Markets in
`Conshohocken today to demonsrate the ease with which anyone can fll
`prescriptions for naloxone, a life-saving opioid overdose reversal drug which is
`readily available to anyone in the commonwealth due to the sanding order signed
`by Dr. Levine.
`
`"The opioid epidemic is the bigges health crisis in Pennsylvania today, requiring
`
`Opiant Exhibit 2163
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 1
`
`
`
`partnerships at every level to efectively combat the deadly disease of addiction,"
`said Dr. Levine. "We thank Dr. Arkoosh and Adapt Pharma for helping so many
`people in our sate obtain the life-saving drug Narcan, or naloxone. Preparing for
`wors case scenarios saves lives and gives victims of overdose a second chance at
`treatment and recovery."
`
`Naloxone is a medication that can reverse an overdose from opioid prescription
`pain medication or heroin. When adminisered during an overdose, naloxone blocks
`the efects of opioids on the brain and resores breathing within two to eight
`minutes. Naloxone has been used safely by medical professionals for more than 40
`years and its only function is to reverse the efects of opioids on the brain and
`respiratory sysem in order to prevent death.
`
`Anyone can obtain naloxone by flling a prescription from a health care provider or
`by using the sanding order issued by Dr. Levine, which serves as a naloxone
`prescription for anyone in the general public to use. The sanding order is kept on
`fle at many pharmacies and can also be downloaded from the Department of
`Health website.
`
`In 2015, while serving as the interim medical director of the county's health
`department, Dr. Arkoosh signed a sanding order to authorize pharmacies to
`disribute naloxone rescue kits to residents in Montgomery County. This predated
`the satewide naloxone sanding order and helped local residents gain access to the
`life-saving drug. Dr. Arkoosh currently serves as chair of the Montgomery County
`Board of Commissioners.
`
`In February 2016, the Wolf Adminisration partnered with Pennsylvania-based
`pharmaceutical company Adapt Pharma to increase satewide access to Narcan, a
`brand of naloxone, including disribution to public high schools. Since that time, 217
`high schools have received Narcan at no cos because of this partnership.
`
`In 2015, nearly 3,500 Pennsylvanians died from a drug overdose. Heroin and opioid
`overdose are the leading cause of accidental death in Pennsylvania, killing more
`
`Opiant Exhibit 2163
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 2
`
`
`
`individuals each year than motor-vehicle accidents.
`
`The Wolf Adminisration holds the fght agains heroin and prescription opioids as a
`top priority.
`
`Some of the adminisration's other initiatives to fght the opioid epidemic include:
`
`Strengthening the Prescription Drug Monitoring Program (PDMP) so that
`doctors are required and able to check the sysem each time they prescribe
`opioids;
`Forming new prescribing guidelines to help doctors who provide opioid
`prescriptions to their patients;
`Creating the warm handof guideline to facilitate referrals from the emergency
`department to subsance abuse treatment; and
`Esablishing a new law limiting the amount of opioids that can be prescribed to
`a minor to seven days.
`
`If you or someone you know is sufering from the disease of addiction, call 1-800-
`662-HELP or visit www.pa.gov/opioids for treatment options. For more information
`on the fght agains opioid abuse in Pennsylvania, visit the Department of Health
`website at www.health.pa.gov or follow us on Facebook and Twitter.
`
`MEDIA CONTACT: April Hutcheson, 717-787-1783
`
`
`
`SOURCE Pennsylvania Department of Health
`
`Related Links
`
`http://www.sate.pa.us
`
`Opiant Exhibit 2163
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 3
`
`
`
`Also from this source
`
`JAN 09, 2017, 13:00 ET
`Department of Health Ofering Free Flu Shots,
`Promoting Opioid...
`
`JAN 04, 2017, 12:01 ET
`Physician General Joins State Veterans Afairs
`Medical Ofcial...
`
`Explore
`
`More news
`releases in similar
`topics
`
`Health Care &
`Hospitals
`
`Medical
`Pharmaceuticals
`
`Pharmaceuticals
`
`Public Safety
`
`You jus read:
`
`Physician General, Montgomery
`County Commissioner and Adapt
`Pharma Representative Fill Naloxone
`Prescription and Discuss the Fight
`agains Pennsylvania's Opioid
`Epidemic
`
`NEWS PROVIDED BY
`Pennsylvania Department of Health
`Jan 11, 2017, 14:30 ET
`
`
`
`
`
`SHARE THIS ARTICLE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Opiant Exhibit 2163
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 4
`
`
`
`Contact
`
`Solutions
`
`About
`
`
`
`888-776-0942
`from 8 AM - 10 PM ET
`Chat Online with an Expert
`Contact Us
`
`Cision Communication
`Cloud™
`For Marketers
`For Public Relations
`For IR & Compliance
`For Agency
`For Small Business
`All Products
`
`About PR Newswire
`About Cision
`Become a Publishing Partner
`Become a Channel Partner
`Careers
`
`Global Sites
`
`My Services
`
`All News Releases
`Online Member Center
`ProfNet℠
`
`Terms of Use
`Site Map
`
`Privacy Policy
`RSS Feeds
`
`Information Security Policy Statement
`
`Copyright © 2017 PR Newswire Association LLC. All Rights Reserved. A
`Cision company.
`
`Opiant Exhibit 2163
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 5
`
`